Saccadic eye movements are controlled by a network of parietal, frontal, striatal, cerebellar and brainstem regions. The saccadic peak velocity is an established biomarker of benzodiazepine effects, with benzodiazepines reliably reducing the peak velocity.
Aims:
In this study, we aimed to replicate the effects of benzodiazepines on peak velocity and we investigated effects on previously less studied measures of saccades. We also explored the roles of sex, task characteristics and the baseline variables age, intelligence and trait anxiety in these effects.
Method:
Healthy adults (N = 34) performed a horizontal step prosaccade task under 1 mg lorazepam, 2 mg lorazepam and placebo in a double-blind, within-subjects design.
Results:
We replicated the dose-dependent reduction in peak velocity with lorazepam and showed that this effect is stronger for saccades to targets at smaller eccentricities. We also demonstrated that this effect is independent of sex and other baseline variables. Lorazepam effects were widespread, however, occurring on mean and variability measures of most saccadic variables. Additionally, there were sex-dependent lorazepam effects on spatial consistency of saccades, indicating more adverse effects in females.
Conclusions:
We conclude that saccadic peak velocity is a sensitive and robust biomarker of benzodiazepine effects. However, lorazepam has pronounced effects also on other parameters of horizontal saccades. Sex-dependent drug effects on spatial consistency may reflect cerebellar mechanisms, given the role of the cerebellum in saccadic spatial accuracy.
AbelMHBrownLK (1998) Validity of the 16PF reasoning scale. Psychol Rep83: 904–906.
2.
AtackJR (2008) GABAA receptor subtype-selective efficacy: TPA023, an a2/a3 selective non-sedating anxiolytic and a5IA, an a5 selective cognition enhancer. CNS Neurosci Ther14: 25–35.
3.
BahillATClarkMRStarkL (1975) The main sequence, a tool for studying human eye movements. Math Biosci24: 191–204.
4.
BallDMGluePWilsonSet al. (1991) Pharmacology of saccadic eye movements in man. 1. Effects of the benzodiazepine receptor ligands midazolam and flumazenil. Psychopharmacology105: 361–367.
5.
BekkerMHJvan Mens-VerhulstJ (2007) Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment. Gend Med4(Suppl B): S178–S193.
6.
BrooksCEClaytonJA (2017) Sex/gender influences on the nervous system: basic steps toward clinical progress. J Neurosci Res95: 14–16.
7.
CarpenterRHS (2004) Contrast, probability, and saccadic latency: evidence for independence of detection and decision. Curr Biol14: 1576–1580.
8.
CattellREberHWTatsuokaMM (1970) Handbook for the 16 Personality Factor Questionnaire. Champaign, IL: Institute for Personality and Ability Testing.
9.
ChenXde HaasSDe KamMet al. (2012) An overview of the CNS-pharmacodynamic profiles of nonselective and selective GABA agonists. Adv Pharmacol Sci2012: 134523.
10.
ChenXJacobsGde KamMet al. (2014) The central nervous system effects of the partial GABA-Aα2,3-selective receptor modulator AZD7325 in comparison with lorazepam in healthy males. Br J Clin Pharmacol78: 1298–1314.
11.
ChenXJacobsGde KamMLet al. (2015) AZD6280, a novel partial gamma-aminobutyric acid: a receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers. J Clin Psychopharmacol35: 22–33.
12.
CoghillDRSethSPedrosoSet al. (2014) Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biol Psychiatry76: 603–615.
13.
CollewijnHErkelensCJSteinmanRM (1988) Binocular co-ordination of human horizontal saccadic eye movements. J Physiol404: 157–182.
14.
De HaasSLde VisserSJvan der PostJPet al. (2007) Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol21: 374–383.
15.
De HaasSLde VisserSJvan der PostJPet al. (2008) Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol22: 24–32.
16.
De HaasSFransonKSchmittJet al. (2009) The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol23: 625–632.
17.
De VisserSJvan der PostJPde WaalPPet al. (2003) Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol55: 39–50.
18.
DiedenhofenBMuschJ (2016) cocron: a web interface and R package for the statistical comparison of Cronbach’s alpha coefficients. Int J Internet Sci11: 51–60.
19.
EttingerUKumariV (2003) Pharmacological studies of smooth pursuit and antisaccade eye movements in schizophrenia: current status and directions for future research. Curr Neuropharmacol1: 285–300.
20.
EttingerUKumariVChitnisXAet al. (2002) Relationship between brain structure and saccadic eye movements in healthy humans. Neurosci Lett328: 225–228.
21.
EttingerUAntonovaECrawfordTJet al. (2005) Structural neural correlates of prosaccade and antisaccade eye movements in healthy humans. Neuroimage24: 487–494.
22.
FuchsAFKanekoCRSScudderCAet al. (1985) Brainstem control of saccadic eye movements. Annu Rev Neurosci8: 307–337.
23.
GieddJNRaznahanAMillsKLet al. (2012) Review: Magnetic resonance imaging of male/female differences in human adolescent brain anatomy. Biol Sex Differ3: 19.
24.
GlueP (1991) Merck, Sharp & Dohme Prize for Young Psychopharmacologists: the pharmacology of saccadic eye movements. J Psychopharmacol5: 377–387.
25.
GreenJFKingDJTrimbleKM (2000) Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam. J Psychopharmacol14: 30–36.
26.
HarronDWHassonBReganMet al. (1995) Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function. J Cardiovasc Pharmacol26(Suppl 2): S48–S54.
27.
HolmqvistKNyströmMAnderssonRet al. (2011) Eye Tracking. Oxford: Oxford University Press.
28.
HuttonSB (2008) Cognitive control of saccadic eye movements. Brain Cogn68: 327–340.
29.
KesslerRCAguilar-GaxiolaSAlonsoJet al. (2011) The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc18: 23–33.
30.
KingDJBestPLynchGet al. (1995) The effects of remoxipride and chlorpromazine on eye movements and psychomotor performance in healthy volunteers. J Psychopharmacol9: 143–149.
31.
KuntsiJKleinC (2012) Intraindividual variability in ADHD and its implications for research of causal links. Curr Top Behav Neurosci9: 67–91.
32.
KyriakopoulosAAGreenblattDJShaderRI (1978) Clinical pharmacokinetics of lorazepam: a review. J Clin Psychiatry39: 16–23.
33.
LeighRJZeeDS (2015) The Neurology of Eye Movements. New York: Oxford University Press.
34.
MassonGSMestreDRMartineauFet al. (2000) Lorazepam-induced modifications of saccadic and smooth-pursuit eye movements in humans: attentional and motor factors. Behav Brain Res108: 169–180.
35.
MinzenbergMJ (2012) Pharmacological MRI approaches to understanding mechanisms of drug action. Curr Top Behav Neurosci11: 365–388.
36.
NathanPJPhanKLHarmerCJet al. (2014) Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. Curr Opin Pharmacol14: 54–61.
37.
OwenDRRupprechtRNuttDJ (2013) Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?J Psychopharmacol27: 119–122.
38.
PerkinsAMEttingerUWeaverKet al. (2013a) Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type. Transl Psychiatry3: e246.
39.
PerkinsAMLeonardAMWeaverKet al. (2013b) A dose of ruthlessness: interpersonal moral judgment is hardened by the anti-anxiety drug lorazepam. J Exp Psychol Gen142: 612–620.
40.
PortNLWurtzRH (2003) Sequential activity of simultaneously recorded neurons in the superior colliculus during curved saccades. J Neurophysiol90: 1887–1903.
41.
ReillyJLLencerRBishopJRet al. (2008) Pharmacological treatment effects on eye movement control. Brain Cogn68: 415–435.
42.
RobinsonFRFuchsAF (2001) The role of the cerebellum in voluntary eye movements. Annu Rev Neurosci24: 981–1004.
43.
Roy-ByrnePPCowleyDSRadantAet al. (1993) Benzodiazepine pharmacodynamics: utility of eye movement measures. Psychopharmacology110: 85–91.
44.
SheligaBMRiggioLRizzolattiG (1994) Orienting of attention and eye movements. Exp Brain Res98: 507–522.
45.
SmitACVan GisbergenJAM (1990) An analysis of curvature in fast and slow human saccades. Exp Brain Res81: 335–345.
SpielbergerCDGorsuchRLLushenePRet al. (1983) Manual for the State-Trait Anxiety Inventory (Form Y). Palo Alto, CA: Consulting Psychologists.
48.
SteeleCJChakravartyMM (2017) Gray-matter structural variability in the human cerebellum: lobule-specific differences across sex and hemisphere. NeuroImage170: 164–173.
49.
SweeneyJABauerKSKeshavanMSet al. (1997) Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients. Neuropsychopharmacology16: 217–228.
50.
TannenbaumCSchwarzJMClaytonJAet al. (2016) Evaluating sex as a biological variable in preclinical research: the devil in the details. Biol Sex Differ7: 13.
51.
TedeschiGSmithATDhillonSet al. (1983) Rate of entrance of benzodiazepines into the brain determined by eye movement recording. Psychol Bull15: 103–107.
52.
TolinDFFoaEB (2006) Sex differences in trauma and posttraumatic stress disorder: a quantitative review of 25 years of research. Psychol Bull132: 959–992.
53.
Uusi-OukariMKorpiER (2010) Regulation of GABAA receptor subunit expression by pharmacological agents. Pharmacol Rev62: 97–135.
54.
VolkowNDWangGJFowlerJSet al. (1997) Gender differences in cerebellar metabolism: test–retest reproducibility. Am J Psychiatry154: 119–121.
55.
WangGJVolkowNDFowlerJSet al. (1998) Evaluation of gender difference in regional brain metabolic responses to lorazepam. Psychiatry Res82: 37–46.
56.
WestheimerG (1954) Mechanism of saccadic eye movements. AMA Arch Ophthalmol52: 710–724.
57.
YarbusAL (1967) Eye Movements and Vision. Boston, MA: Springer US.
58.
YonkersKAKandoJCColeJOet al. (1992) Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry149: 587–595.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
